Developer docs
API playgroundTry for free, no card

Search company profiles

Coave Therapeutics

Full company profile

uuid0002e2i

Namestring
Coave Therapeutics
Legal namestring
Coave Therapeutics SA
Websiteurl
coavetx.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Coave Therapeutics SA is a Paris-based, clinical-stage biotechnology company founded in 2014 (originally as Horama, rebranded in July 2021) that develops gene therapies for rare ocular and central nervous system diseases. Its core technology is the proprietary ALIGATER™ platform, which chemically conjugates peptide-based ligands onto AAV capsids or lipid nanoparticles to produce tissue-targeted Precision Vectors that the company positions as safer and more efficient than traditional AAV approaches. The platform underpins a pipeline spanning CTx-PDE6b in Phase I/II for retinitis pigmentosa (positive 12-month data in 17 patients), CoTx-101 for wet AMD and diabetic macular edema using a first-in-class suprachoroidal vector (preclinical, IND-targeted for 2027), CTx-TFEB for ALS (preclinical, funded by a $2.9M ALS Association grant), CTx-GBA1 for Parkinson's and Gaucher disease, CTx-ABCA4 for Stargardt's disease, plus the coAAV-CSF-01 brain-targeted vector and the upcoming OneAAV™ universal capsid.

The company's business model combines retained commercial rights in major markets (US, Japan, South Korea, China) with exclusive regional licensing. The defining transaction is the September 2021 agreement with Théa Open Innovation for CTx-PDE6b in Europe, which delivered a €10 million upfront plus equity and eligibility for up to €65 million in development, regulatory, and commercial milestones plus royalties. Manufacturing is secured through a strategic collaboration with ABL at OXB's Lyon facility, which grants Coave exclusive option on process development capacity. To date, Coave has raised approximately €65 million across venture rounds (notably a €33.1M Series B in July 2021 led by Seroba Life Sciences and a €32M Series A in January 2025 led by Novo Holdings and Bpifrance) and has begun commercial-stage positioning through the April 2025 appointment of a US-based VP Business Development from Alexion.

Short descriptiontext

Coave Therapeutics is a Paris-based clinical-stage biotech developing ligand-conjugated AAV gene therapies via its ALIGATER™ platform for rare ocular and CNS diseases, with CTx-PDE6b in Phase I/II and a preclinical pipeline spanning wet AMD, ALS, Parkinson's, and Stargardt's.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene therapy, AAV vector platform, ocular gene therapy, CNS gene therapy, rare disease therapeutics
Industry5 codes
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAL
Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Gene Therapy / Rare Disease Biopharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Gene Therapy Product Sales
TypeOne Time License
Description

Direct commercialization of proprietary gene therapy products in retained territories. Coave retains commercial rights to CTx-PDE6b in US, Japan, South Korea, China and other territories outside Europe.

globenewswire.com
2Licensing and Milestone Payments
TypeLicensing Royalties
Description

Exclusive licensing agreements with upfront payments, development/regulatory/commercial milestone payments, and sales royalties. Example: Upfront payment of €10 million plus milestone payments up to €65 million plus royalties from Théa Open Innovation for CTx-PDE6b European rights.

coavetx.com
3Platform Licensing
TypeLicensing Royalties
Description

ALIGATER platform technology can be applied to any vector regardless of administration route or target tissue, enabling exploration of prevalent indications and potential platform licensing opportunities.

coavetx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1ALIGATER
Description

Proprietary AAV-Ligand Conjugate platform enabling targeted gene delivery through chemically modified AAV capsids for precision vectors that are highly tissue specific.

coavetx.com
Core offering1 text field

Coave Therapeutics develops clinical and preclinical AAV-based gene therapies for rare inherited ocular and CNS diseases, powered by its proprietary ALIGATER™ ligand-conjugated AAV delivery platform. Its lead clinical program CTx-PDE6b is in Phase I/II for PDE6b retinitis pigmentosa, and it is advancing CoTx-101 for retinal vascular diseases (wet AMD, DME) using a first-in-class suprachoroidal vector, alongside preclinical programs for ALS, Parkinson's/Gaucher, Stargardt's and CNS indications. The platform is also positioned for licensing to other gene therapy developers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • ≥70% of patients injection-free at one year
+2 more records
Product overview1 text field

Coave Therapeutics is a clinical-stage biotechnology company developing gene therapies for rare ocular and CNS diseases. Its core technology is the ALIGATER™ platform, a proprietary AAV-Ligand Conjugate system that chemically modifies AAV capsids for enhanced targeted delivery. The company operates a pipeline model with its lead clinical product CTx-PDE6b (retinitis pigmentosa, Phase I/II) and emerging lead CoTx-101 (retinal vascular diseases). Preclinical programs include CTx-TFEB (ALS), CTx-GBA1 (Parkinson's/Gaucher), and CTx-ABCA4 (Stargardt's). The company has also developed coAAV-CSF-01 for brain-targeted delivery and announced OneAAV™ universal capsid for future generations of gene therapy vectors.

Product and service7 records
1CTx-PDE6b
CategoryGene Therapy — Clinical Stage Product
Description

AAV5-based gene therapy delivering a functional copy of the human PDE6b gene to photoreceptor cells of patients with retinitis pigmentosa caused by bi-allelic mutations in the PDE6b gene. Currently in Phase I/II clinical trials. European commercial rights licensed to Théa Open Innovation; Coave retains rights in US, Japan, South Korea, China and other territories.

2CoTx-101
CategoryGene Therapy — Preclinical Lead Program
Description

Lead gene therapy program for retinal vascular diseases including neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Powered by Coave's first-in-class precision suprachoroidal AAV delivery vector enabling in-office administration, deep retinal penetration, broad tissue coverage and sustained expression of two clinically validated anti-angiogenesis biologics.

3coAAV-CSF-01
CategoryGene Therapy Vector — Platform Asset
Description

Novel brain-targeted gene therapy vector launched from the ALIGATER platform for neurodegenerative and other CNS diseases. Represents an additional CNS-targeted coAAV capsid for the company.

4OneAAV™ Universal Capsid
CategoryGene Therapy Vector — Platform Asset
Description

Next-generation universal capsid technology representing the third generation of Coave's gene therapy vector platform, designed to expand the range of indications and delivery routes addressable with the ALIGATER platform.

5CTx-TFEB
CategoryGene Therapy — Preclinical Program
Description

Preclinical gene therapy program for amyotrophic lateral sclerosis (ALS) that aims to promote autophagy by delivering the TFEB gene to neurons, with the goal of potentially treating all forms of ALS. Supported by $2.9M grant from the ALS Association.

6CTx-GBA1
CategoryGene Therapy — Preclinical Program
Description

Preclinical gene therapy program for Parkinson's disease and Gaucher Disease using AAV-Ligand Conjugate capsids from the ALIGATER platform.

7CTx-ABCA4
CategoryGene Therapy — Preclinical Program
Description

Preclinical gene therapy program for Stargardt's disease using AAV-Ligand Conjugate capsids from the ALIGATER platform.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-09-21
Description

Founding science from University of Nantes underlies Coave's ALIGATER platform technology. Lolita Petit, CSO, obtained PhD in Biotechnologies and Therapeutics from University of Nantes.

2Institute of Neurodegenerative Diseases (IMN) - University of Bordeaux/CNRS
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-09-12
Description

Collaboration to develop gene therapy programs targeting protein degradation in neurodegenerative disorders. Explores TFEB gene therapy for alpha-synucleinopathies such as MSA and Parkinson's disease. IMN conducts in vivo studies using Coave's ALIGATER platform for coAAV vectors carrying TFEB gene.

coavetx.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-06-09
Description

Strategic collaboration to develop gene therapy manufacturing processes and create joint capabilities for process development of AAV-based products. Two-stage collaboration combines complementary expertise with co-development teams working in ABL's GMP facility in Lyon. Provides Coave exclusive option for process development capacity and laboratory space.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2021-09-16
Description

Exclusive licensing, co-development and commercialization agreement for CTx-PDE6b in Europe. Coave received €10 million upfront payment and equity investment, eligible for up to €65 million in milestones plus royalties. Théa gains rights to commercialize in EU and certain territories while Coave retains rights in US, Japan, South Korea, China and rest of world.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based therapies for ocular diseases (including retinitis pigmentosa) and CNS disorders, with a pipeline of candidates addressing inherited retinal diseases and neurodegenerative conditions — directly comparable to Coave's ocular + CNS AAV focus.

TypeDirect peer
Description

Clinical-stage biotech focused on AAV-based gene therapies for ocular and CNS diseases, with pipeline assets in inherited retinal diseases and Alzheimer's disease — most direct US-side comparable to Coave's platform and indication strategy.

TypeDirect peer
Description

European clinical-stage gene therapy company developing AAV-based therapies for retinal diseases, including Leber hereditary optic neuropathy and retinitis pigmentosa — directly comparable on indication, modality, and European clinical-stage positioning.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV vectors for ocular diseases, including wet AMD and diabetic macular edema — directly comparable to Coave's CoTx-101 retinal vascular disease program and suprachoroidal/intravitreal delivery approach.

TypeDirect peer
Description

Clinical-stage gene therapy company with a proprietary engineered AAV capsid platform targeting ophthalmology (wet AMD, RP) and CNS indications — most directly comparable on the platform-modality angle, leveraging custom capsid libraries to address ocular and CNS tissues.

TypeDirect peer
Description

Clinical-stage AAV gene therapy company focused on CNS neurodegenerative diseases including frontotemporal dementia and ALS — directly comparable on the CNS/AAV axis and overlapping with Coave's CTx-TFEB ALS program.

TypeBroad incumbent
Description

Pioneer in ocular AAV gene therapy (Luxturna for RPE65 IRD) and broader gene therapy platform now under Roche — comparable on ocular AAV gene therapy modality and leadership bench (Coave's CSO Lolita Petit was previously at Spark).

TypeBroad incumbent
Description

Established AAV gene therapy platform company with multiple clinical programs in ocular (wet AMD via ABBV-RGX-314) and CNS diseases — comparable as a broader AAV platform incumbent, and Olivier Danos (Coave board member) currently serves as RegenxBio's CSO.

TypeEmerging player
Description

Emerging gene therapy company developing engineered AAV capsids for ophthalmology, CNS, and metabolic diseases — comparable on the AAV platform + ocular/CNS indication overlap and on capital scale as a privately held clinical-stage peer.

TypeDirect peer
Description

Was a clinical-stage AAV gene therapy company focused on inherited retinal diseases (choroideremia, X-linked retinitis pigmentosa), acquired by Biogen in 2019 — historically the most direct ocular AAV gene therapy comparable and a useful benchmark for M&A exit dynamics in this space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Coave Therapeutics

Gene Therapy / Rare Disease Biopharmaceuticalscoavetx.com

Coave Therapeutics is a Paris-based clinical-stage biotech developing ligand-conjugated AAV gene therapies via its ALIGATER™ platform for rare ocular and CNS diseases, with CTx-PDE6b in Phase I/II and a preclinical pipeline spanning wet AMD, ALS, Parkinson's, and Stargardt's.

What Coave Therapeutics does

Coave Therapeutics SA is a Paris-based, clinical-stage biotechnology company founded in 2014 (originally as Horama, rebranded in July 2021) that develops gene therapies for rare ocular and central nervous system diseases. Its core technology is the proprietary ALIGATER™ platform, which chemically conjugates peptide-based ligands onto AAV capsids or lipid nanoparticles to produce tissue-targeted Precision Vectors that the company positions as safer and more efficient than traditional AAV approaches. The platform underpins a pipeline spanning CTx-PDE6b in Phase I/II for retinitis pigmentosa (positive 12-month data in 17 patients), CoTx-101 for wet AMD and diabetic macular edema using a first-in-class suprachoroidal vector (preclinical, IND-targeted for 2027), CTx-TFEB for ALS (preclinical, funded by a $2.9M ALS Association grant), CTx-GBA1 for Parkinson's and Gaucher disease, CTx-ABCA4 for Stargardt's disease, plus the coAAV-CSF-01 brain-targeted vector and the upcoming OneAAV™ universal capsid.

The company's business model combines retained commercial rights in major markets (US, Japan, South Korea, China) with exclusive regional licensing. The defining transaction is the September 2021 agreement with Théa Open Innovation for CTx-PDE6b in Europe, which delivered a €10 million upfront plus equity and eligibility for up to €65 million in development, regulatory, and commercial milestones plus royalties. Manufacturing is secured through a strategic collaboration with ABL at OXB's Lyon facility, which grants Coave exclusive option on process development capacity. To date, Coave has raised approximately €65 million across venture rounds (notably a €33.1M Series B in July 2021 led by Seroba Life Sciences and a €32M Series A in January 2025 led by Novo Holdings and Bpifrance) and has begun commercial-stage positioning through the April 2025 appointment of a US-based VP Business Development from Alexion.

Coave Therapeutics firmographics

Firmographics
Name
Coave Therapeutics
Legal name
Coave Therapeutics SA
Website
https://coavetx.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
Coave Therapeutics is a Paris-based clinical-stage biotech developing ligand-conjugated AAV gene therapies via its ALIGATER™ platform for rare ocular and CNS diseases, with CTx-PDE6b in Phase I/II and a preclinical pipeline spanning wet AMD, ALS, Parkinson's, and Stargardt's.
Ownership category
akta.pro rank

Coave Therapeutics industry classification

Industry
Product category
Gene Therapy / Rare Disease Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAL
Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Gene therapy
  • AAV vector platform
  • Ocular gene therapy
  • CNS gene therapy
  • Rare disease therapeutics

Where Coave Therapeutics is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices3 records

Markets served

Coave Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Gene Therapy Product Sales: Direct commercialization of proprietary gene therapy products in retained territories. Coave retains commercial rights to CTx-PDE6b in US, Japan, South Korea, China and other territories outside Europe.
  2. Licensing and Milestone Payments: Exclusive licensing agreements with upfront payments, development/regulatory/commercial milestone payments, and sales royalties. Example: Upfront payment of €10 million plus milestone payments up to €65 million plus royalties from Théa Open Innovation for CTx-PDE6b European rights.
  3. Platform Licensing: ALIGATER platform technology can be applied to any vector regardless of administration route or target tissue, enabling exploration of prevalent indications and potential platform licensing opportunities.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Coave Therapeutics product offering

Product offering

Core offering

Coave Therapeutics develops clinical and preclinical AAV-based gene therapies for rare inherited ocular and CNS diseases, powered by its proprietary ALIGATER™ ligand-conjugated AAV delivery platform. Its lead clinical program CTx-PDE6b is in Phase I/II for PDE6b retinitis pigmentosa, and it is advancing CoTx-101 for retinal vascular diseases (wet AMD, DME) using a first-in-class suprachoroidal vector, alongside preclinical programs for ALS, Parkinson's/Gaucher, Stargardt's and CNS indications. The platform is also positioned for licensing to other gene therapy developers.

Product overview

Coave Therapeutics is a clinical-stage biotechnology company developing gene therapies for rare ocular and CNS diseases. Its core technology is the ALIGATER™ platform, a proprietary AAV-Ligand Conjugate system that chemically modifies AAV capsids for enhanced targeted delivery. The company operates a pipeline model with its lead clinical product CTx-PDE6b (retinitis pigmentosa, Phase I/II) and emerging lead CoTx-101 (retinal vascular diseases). Preclinical programs include CTx-TFEB (ALS), CTx-GBA1 (Parkinson's/Gaucher), and CTx-ABCA4 (Stargardt's). The company has also developed coAAV-CSF-01 for brain-targeted delivery and announced OneAAV™ universal capsid for future generations of gene therapy vectors.

Differentiator

Problem solved

Functional benefit

Brands

  • ALIGATER: Proprietary AAV-Ligand Conjugate platform enabling targeted gene delivery through chemically modified AAV capsids for precision vectors that are highly tissue specific.

Products and services

  • CTx-PDE6b AAV5-based gene therapy delivering a functional copy of the human PDE6b gene to photoreceptor cells of patients with retinitis pigmentosa caused by bi-allelic mutations in the PDE6b gene. Currently in Phase I/II clinical trials. European commercial rights licensed to Théa Open Innovation; Coave retains rights in US, Japan, South Korea, China and other territories.
  • CoTx-101 Lead gene therapy program for retinal vascular diseases including neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Powered by Coave's first-in-class precision suprachoroidal AAV delivery vector enabling in-office administration, deep retinal penetration, broad tissue coverage and sustained expression of two clinically validated anti-angiogenesis biologics.
  • coAAV-CSF-01 Novel brain-targeted gene therapy vector launched from the ALIGATER platform for neurodegenerative and other CNS diseases. Represents an additional CNS-targeted coAAV capsid for the company.
  • OneAAV™ Universal Capsid Next-generation universal capsid technology representing the third generation of Coave's gene therapy vector platform, designed to expand the range of indications and delivery routes addressable with the ALIGATER platform.
  • CTx-TFEB Preclinical gene therapy program for amyotrophic lateral sclerosis (ALS) that aims to promote autophagy by delivering the TFEB gene to neurons, with the goal of potentially treating all forms of ALS. Supported by $2.9M grant from the ALS Association.
  • CTx-GBA1 Preclinical gene therapy program for Parkinson's disease and Gaucher Disease using AAV-Ligand Conjugate capsids from the ALIGATER platform.
  • CTx-ABCA4 Preclinical gene therapy program for Stargardt's disease using AAV-Ligand Conjugate capsids from the ALIGATER platform.

Quantifiable outcome

  • ≥70% of patients injection-free at one year
  • +2 more outcomes

Companies that use Coave Therapeutics

Customer profile

Segments3 records

Ideal customer profiles3 records

Coave Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Coave Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and flagship.

  • University of NantescoreTechnology or Integration · 21 September 2023Founding science from University of Nantes underlies Coave's ALIGATER platform technology. Lolita Petit, CSO, obtained PhD in Biotechnologies and Therapeutics from University of Nantes.
  • Institute of Neurodegenerative Diseases (IMN) - University of Bordeaux/CNRScoreStrategic or Co-development Partner · 12 September 2022Collaboration to develop gene therapy programs targeting protein degradation in neurodegenerative disorders. Explores TFEB gene therapy for alpha-synucleinopathies such as MSA and Parkinson's disease. IMN conducts in vivo studies using Coave's ALIGATER platform for coAAV vectors carrying TFEB gene.
  • ABLcoreTechnology or Integration · 9 June 2022Strategic collaboration to develop gene therapy manufacturing processes and create joint capabilities for process development of AAV-based products. Two-stage collaboration combines complementary expertise with co-development teams working in ABL's GMP facility in Lyon. Provides Coave exclusive option for process development capacity and laboratory space.
  • Théa Open InnovationflagshipStrategic or Co-development Partner · 16 September 2021Exclusive licensing, co-development and commercialization agreement for CTx-PDE6b in Europe. Coave received €10 million upfront payment and equity investment, eligible for up to €65 million in milestones plus royalties. Théa gains rights to commercialize in EU and certain territories while Coave retains rights in US, Japan, South Korea, China and rest of world.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Coave Therapeutics competitors and assessment

Company assessment

Direct peers

  • MeiraGTx Holdings: Clinical-stage gene therapy company developing AAV-based therapies for ocular diseases (including retinitis pigmentosa) and CNS disorders, with a pipeline of candidates addressing inherited retinal diseases and neurodegenerative conditions — directly comparable to Coave's ocular + CNS AAV focus.
  • Lexeo Therapeutics: Clinical-stage biotech focused on AAV-based gene therapies for ocular and CNS diseases, with pipeline assets in inherited retinal diseases and Alzheimer's disease — most direct US-side comparable to Coave's platform and indication strategy.
  • GenSight Biologics: European clinical-stage gene therapy company developing AAV-based therapies for retinal diseases, including Leber hereditary optic neuropathy and retinitis pigmentosa — directly comparable on indication, modality, and European clinical-stage positioning.
  • Adverum Biotechnologies: Clinical-stage gene therapy company developing AAV vectors for ocular diseases, including wet AMD and diabetic macular edema — directly comparable to Coave's CoTx-101 retinal vascular disease program and suprachoroidal/intravitreal delivery approach.
  • 4D Molecular Therapeutics: Clinical-stage gene therapy company with a proprietary engineered AAV capsid platform targeting ophthalmology (wet AMD, RP) and CNS indications — most directly comparable on the platform-modality angle, leveraging custom capsid libraries to address ocular and CNS tissues.
  • AviadoBio: Clinical-stage AAV gene therapy company focused on CNS neurodegenerative diseases including frontotemporal dementia and ALS — directly comparable on the CNS/AAV axis and overlapping with Coave's CTx-TFEB ALS program.
  • Nightstar Therapeutics (acquired by Biogen): Was a clinical-stage AAV gene therapy company focused on inherited retinal diseases (choroideremia, X-linked retinitis pigmentosa), acquired by Biogen in 2019 — historically the most direct ocular AAV gene therapy comparable and a useful benchmark for M&A exit dynamics in this space.

Broad incumbents

  • Spark Therapeutics (Roche): Pioneer in ocular AAV gene therapy (Luxturna for RPE65 IRD) and broader gene therapy platform now under Roche — comparable on ocular AAV gene therapy modality and leadership bench (Coave's CSO Lolita Petit was previously at Spark).
  • RegenxBio: Established AAV gene therapy platform company with multiple clinical programs in ocular (wet AMD via ABBV-RGX-314) and CNS diseases — comparable as a broader AAV platform incumbent, and Olivier Danos (Coave board member) currently serves as RegenxBio's CSO.

Emerging players

  • Kriya Therapeutics: Emerging gene therapy company developing engineered AAV capsids for ophthalmology, CNS, and metabolic diseases — comparable on the AAV platform + ocular/CNS indication overlap and on capital scale as a privately held clinical-stage peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Coave Therapeutics social profiles

Digital presence

Coave Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Coave Therapeutics leadership team

Management profile

Number of profiles

Profiles15 records

Coave Therapeutics funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Coave Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Coave Therapeutics

What does Coave Therapeutics do?

Coave Therapeutics develops clinical and preclinical AAV-based gene therapies for rare inherited ocular and CNS diseases, powered by its proprietary ALIGATER™ ligand-conjugated AAV delivery platform. Its lead clinical program CTx-PDE6b is in Phase I/II for PDE6b retinitis pigmentosa, and it is advancing CoTx-101 for retinal vascular diseases (wet AMD, DME) using a first-in-class suprachoroidal vector, alongside preclinical programs for ALS, Parkinson's/Gaucher, Stargardt's and CNS indications. The platform is also positioned for licensing to other gene therapy developers.

Is Coave Therapeutics a public or private company?

Coave Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Coave Therapeutics founded?

Coave Therapeutics was founded in 2014. It employs 51 to 100 people.

Where is Coave Therapeutics based?

Coave Therapeutics is headquartered in Paris, France, in the Europe region.

How does Coave Therapeutics make money?

Three revenue lines are on record. Gene Therapy Product Sales are the primary driver. The others are licensing and Milestone Payments and platform Licensing.

Who are Coave Therapeutics's main competitors?

Direct peers on record are MeiraGTx Holdings, Lexeo Therapeutics, GenSight Biologics, Adverum Biotechnologies, 4D Molecular Therapeutics, AviadoBio and Nightstar Therapeutics (acquired by Biogen). Broad incumbents are Spark Therapeutics (Roche) and RegenxBio. Kriya Therapeutics is listed as an emerging player.

Does Coave Therapeutics have an API?

No public API is recorded for Coave Therapeutics.

What industry is Coave Therapeutics in?

Coave Therapeutics's product category is Gene Therapy / Rare Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers, with a secondary code of HLAAACAG, Ophthalmology Gene Therapies. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceCoave Therapeutics Strengthens Leadership Team to Advance Lead Gene Therapy Program into the ClinicCoave Therapeutics appointed four senior executives to advance its lead retinal gene therapy program, CoTx-101, toward clinical development. The appointments include Carl De Luca as CTO, Nora Dimon as VP of Clinical Development, Annelise Brossel as VP of Regulatory and Translational Sciences, and Veronica Ferrer as VP of Global Operations. The company aims to expand its pipeline to broader retinal diseases.GlobeNewswireCoave Therapeutics to unveil OneAAVTM universal capsid at ASGCT 2026, paving the way for third generation gene therapy vectorsCoave Therapeutics will present data on its OneAAVTM universal capsid at ASGCT 2026, showing ligand-conjugated vectors enable brain transduction with up to 1000x lower liver transduction. The company also plans to showcase its suprachoroidal vector and lead program CoTx-101 for retinal vascular diseases.GlobeNewswireCoave Therapeutics to present two posters at ARVO 2026, on first-in-class ligand-conjugated suprachoroidal vector and lead gene therapy programCoave Therapeutics will present two posters and a company presentation at ARVO 2026 in Denver, covering its first-in-class ligand-conjugated suprachoroidal vector coAAV-SCS and lead program CoTx-101 for wet AMD. The posters detail preclinical data on the vector's posterior segment targeting and CoTx-101's dual-pathway gene therapy for retinal vascular diseases.openPR.comCoave Therapeutics "CTx PDE6B" Market size expansion of Several Folds by 2034DelveInsight published a market research report forecasting the commercial potential of CTx PDE6B, Coave Therapeutics' investigational gene therapy for retinitis pigmentosa caused by PDE6B mutations, through 2034 across the seven major markets. The Phase I/II trial (n=17) demonstrated positive results with improvements across all five key endpoints in a subgroup with less advanced disease, and regulatory approval was obtained to expand the trial to younger patients aged 13-25 years. The report provides sales forecasts from 2028 to 2034, competitive landscape analysis, and supports Coave's preparations for a registrational trial.CoavetxCoave Therapeutics – Coave Therapeutics is a clinical stage biotechnology company focused on developing life changing gene therapies in rare ocular and CNS (Central Nervous System) diseases.Coave Therapeutics, a biotech company, is developing targeted gene therapies primarily for retinal vascular diseases like AMD and DME, using its proprietary ALIGATER™ platform. Its lead program, CoTx-101, aims to provide durable, safe, and minimally invasive treatment with the potential to significantly reduce treatment burden. The company's innovative delivery technology enables in-office gene therapy injections, with a focus on safety, efficacy, and ease of administration.BioSpaceCoave Therapeutics unveils lead gene therapy program for retinal vascular diseases, powered by first-in-class vector for suprachoroidal deliveryCoave Therapeutics announced the nomination of its lead gene therapy program, CoTx-101, for treating retinal vascular diseases such as wet age-related macular degeneration and diabetic macular edema. The therapy uses a proprietary vector for suprachoroidal delivery, aiming to provide durable, safe, and effective in-office treatment. The company plans to validate its studies in 2026 and aims to be IND-ready in 2027.GlobeNewswireCoave Therapeutics unveils lead gene therapy program for retinal vascular diseases, powered by first-in-class vector for suprachoroidal deliveryCoave Therapeutics, a Paris-based gene therapy company, announced the nomination of CoTx-101 as its lead program for retinal vascular diseases including wet age-related macular degeneration and diabetic macular edema, powered by its proprietary suprachoroidal vector (coAAV-SCS). The novel vector demonstrated unprecedented transduction efficacy and immune evasion in non-human primate studies, potentially enabling an in-office procedure that combines the durability of gene therapy with the efficacy and safety of biologics, addressing a significant treatment burden where over 40% of patients discontinue current anti-VEGF therapies within the first year. The company plans to complete TPP validation in 2026 and aims to be IND-ready by 2027.GlobeNewswireCoave Therapeutics demonstrates superiority of its novel suprachoroidal capsid at ESGCT Congress 2025Coave Therapeutics will present data on its lead suprachoroidal capsid coAAV-SCS-01 at the ESGCT Congress 2025 in Seville. The capsid outperformed other capsids by up to 26x in targeting RPE-choroid and retinal cells in non-human primate studies, with improved safety and immune evasion. The data suggests potential for safe second-eye treatment.GlobeNewswireCoave Therapeutics Establishes New Scientific Advisory Board to Accelerate Innovation in Genetic Medicines for Eye and CNS DiseasesCoave Therapeutics announced a new Scientific Advisory Board to guide its gene therapy pipeline for eye and CNS diseases. The board includes Olivier Danos, Robin Ali, and others, and will support its ALIGATER platform for extra-hepatic delivery.GlobeNewswireCoave Therapeutics Establishes New Scientific Advisory Board to Accelerate Innovation in Genetic Medicines for Eye and CNS DiseasesCoave Therapeutics announced a new Scientific Advisory Board to guide its gene therapy pipeline for eye and CNS diseases. The board includes experts in AAV vector biology and extra-hepatic delivery, supporting its ALIGATER platform. The company aims to advance precision and safety in genetic medicines.